---
layout: default
title: Hydroxyprogesterone Caproate
description: "Hydroxyprogesterone Caproate çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 82
evidence_level: L3
indication_count: 10
---

# Hydroxyprogesterone Caproate

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Hydroxyprogesterone Caproateï¼šå¾æµç”¢é é˜²åˆ°å­å®®å…§è†œç™Œ

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Hydroxyprogesterone Caproate å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Hydroxyprogesterone caproate åŸæœ¬ç”¨æ–¼é é˜²ç¿’æ…£æ€§æµç”¢å’Œæ²»ç™‚æ©Ÿèƒ½æ€§å­å®®å‡ºè¡€ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**å­å®®å…§è†œç™Œ (endometrial cancer)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **1 å€‹è‡¨åºŠè©¦é©—**å’Œ **è¶…é 20 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | ç¿’æ…£æ€§æµç”¢ã€æ©Ÿèƒ½æ€§å­å®®å‡ºè¡€ã€é»ƒé«”æ©Ÿèƒ½ä¸å…¨ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | å­å®®å…§è†œç™Œ (endometrial cancer) |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.96% |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | æœ‰æ•ˆè¨±å¯è­‰ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µï¼ˆéƒ¨åˆ†å·²è¨»éŠ·ï¼‰ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. endometriosis of uterus</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.98%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Hydroxyprogesterone caproateï¼ˆ17-OHP caproateï¼‰æ˜¯ä¸€ç¨®é•·æ•ˆå‹é»ƒé«”ç´ è£½åŠ‘ï¼Œ
é€éèˆ‡é»ƒé«”ç´ å—é«”çµåˆï¼ŒæŠ‘åˆ¶å­å®®å…§è†œå¢ç”Ÿä¸¦èª˜å°åˆ†åŒ–ã€‚

**é æ¸¬åˆç†æ€§åˆ†æï¼š**
- å­å®®å…§è†œç™Œå¤šç‚ºè·çˆ¾è’™ä¾è³´æ€§è…«ç˜¤ï¼Œé»ƒé«”ç´ æ²»ç™‚æ˜¯å·²çŸ¥æœ‰æ•ˆç­–ç•¥
- é«˜åˆ†åŒ–å­å®®å…§è†œç™Œå°é»ƒé«”ç´ æ²»ç™‚åæ‡‰è‰¯å¥½
- é»ƒé«”ç´ å¯èª˜å°å­å®®å…§è†œç™Œç´°èƒçš„åˆ†åŒ–å’Œå‡‹äº¡
- æ­¤é æ¸¬åæ˜ çš„æ˜¯å·²æœ‰è±å¯Œè‡¨åºŠç¶“é©—çš„é©æ‡‰ç—‡

**æ©Ÿè½‰æ”¯æŒï¼š**
- æŠ‘åˆ¶é›Œæ¿€ç´ åˆºæ¿€çš„å­å®®å…§è†œå¢ç”Ÿ
- èª˜å°å­å®®å…§è†œç™Œç´°èƒåˆ†åŒ–ï¼ˆç”± PMID: 6836982 ç­‰å¤šç¯‡æ–‡ç»æ”¯æŒï¼‰
- èˆ‡ Tamoxifen è¯åˆä½¿ç”¨å¯å¢å¼·ç™‚æ•ˆï¼ˆPMID: 2815695ï¼‰

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT01812161](https://clinicaltrials.gov/study/NCT01812161) | N/A | COMPLETED | 54 | é›»é‡ç¸å° PCOS æ‚£è€… 17-OHP æ°´å¹³çš„å½±éŸ¿ï¼ˆé–“æ¥ç›¸é—œï¼‰ |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [10796737](https://pubmed.ncbi.nlm.nih.gov/10796737/) | 2000 | Cochrane ç³»çµ±å›é¡§ | Cochrane Database | é»ƒé«”ç´ ç”¨æ–¼å­å®®å…§è†œç™Œçš„è¡“å¾Œè¼”åŠ©æ²»ç™‚ |
| [21154390](https://pubmed.ncbi.nlm.nih.gov/21154390/) | 2010 | Cochrane ç³»çµ±å›é¡§ | Cochrane Database | æ™šæœŸæˆ–å¾©ç™¼æ€§å­å®®å…§è†œç™Œçš„è·çˆ¾è’™æ²»ç™‚ |
| [8500499](https://pubmed.ncbi.nlm.nih.gov/8500499/) | 1993 | RCT | Eur J Gynaecol Oncol | OPC èˆ‡ Tamoxifen è¯åˆæ²»ç™‚å¯æé«˜ 5 å¹´å­˜æ´»ç‡ 19% |
| [22245711](https://pubmed.ncbi.nlm.nih.gov/22245711/) | 2012 | ç³»çµ±å›é¡§ | Gynecol Oncol | é»ƒé«”ç´ æ²»ç™‚å­å®®å…§è†œå¢ç”Ÿå’Œç¬¬ä¸€æœŸè…ºç™Œçš„è…«ç˜¤å­¸åŠç”Ÿæ®–çµæœ |
| [19591991](https://pubmed.ncbi.nlm.nih.gov/19591991/) | 2009 | å›é¡§æ€§ç ”ç©¶ | Fertil Steril | å¹´è¼•å¥³æ€§é«˜åˆ†åŒ–å­å®®å…§è†œç™Œçš„ä¿ç•™ç”Ÿè‚²æ²»ç™‚ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. renal hypoplasia, bilateral</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.97%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. endometriosis in cutaneous scar</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.97%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. endometriosis of rectovaginal septum and vagina</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.97%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. renal hypoplasia (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.97%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. uterine corpus cancer</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.96%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.96%
- **è­‰æ“šç­‰ç´š**ï¼šL4ï¼ˆæœ‰æ–‡ç»æ”¯æŒï¼‰

### è‡¨åºŠè­‰æ“š

**ç›¸é—œæ–‡ç»**ï¼šå…± 9 ç¯‡


</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. cervix endometriosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.96%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.96%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. endometrial cancer</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.96%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.96%
- **è­‰æ“šç­‰ç´š**ï¼šL3ï¼ˆæœ‰è‡¨åºŠè©¦é©—é€²è¡Œä¸­ï¼‰

### è‡¨åºŠè­‰æ“š

**è‡¨åºŠè©¦é©—**ï¼šå…± 1 é …

- è©¦é©—éšæ®µåˆ†å¸ƒï¼šNA: 1é …

**ç›¸é—œæ–‡ç»**ï¼šå…± 20 ç¯‡


</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. breast fibrocystic disease</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.96%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.96%
- **è­‰æ“šç­‰ç´š**ï¼šL4ï¼ˆæœ‰æ–‡ç»æ”¯æŒï¼‰

### è‡¨åºŠè­‰æ“š

**ç›¸é—œæ–‡ç»**ï¼šå…± 1 ç¯‡


</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. infantile cerebral and cerebellar atrophy with postnatal progressive microcephaly</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.94%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›ç½²è—¥è£½å­—ç¬¬005995è™Ÿ | ç¢ºæ™®æ¦®æ³¨å°„æ¶² | æ³¨å°„åŠ‘ | å…ˆå…†æµç”¢ã€ç¿’æ…£æµç”¢ã€å­å®®æ©Ÿèƒ½æ€§å‡ºè¡€ã€ç—›ç¶“ |
| è¡›ç½²è—¥è£½å­—ç¬¬025803è™Ÿ | æ™®å¯¶èƒæ³¨å°„æ¶²125æ¯«å…‹/æ¯«å‡ | æ³¨å°„åŠ‘ | ç„¡æœˆç¶“ã€æ©Ÿèƒ½æ€§å­å®®å‡ºè¡€ã€åˆ‡è¿«æµç”¢ã€ç¿’æ…£æ€§æµç”¢ |

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼šæœªåœ¨ DDI è³‡æ–™åº«ä¸­æ‰¾åˆ°é‡å¤§äº¤äº’ä½œç”¨
- **æ³¨æ„äº‹é …**ï¼š
  - å¯èƒ½å¢åŠ è¡€æ “æ “å¡é¢¨éšª
  - é•·æœŸä½¿ç”¨éœ€ç›£æ¸¬è‚åŠŸèƒ½
  - è·çˆ¾è’™æ²»ç™‚å‰éœ€ç¢ºèªè…«ç˜¤çš„è·çˆ¾è’™å—é«”ç‹€æ…‹
- **å­å®®å…§è†œç™Œé©ç”¨æ¢ä»¶**ï¼š
  - é©ç”¨æ–¼é«˜åˆ†åŒ–ï¼ˆGrade 1ï¼‰è…«ç˜¤
  - é»ƒé«”ç´ å—é«”é™½æ€§è€…åæ‡‰è¼ƒä½³
  - å¯ä½œç‚ºæ‰‹è¡“çš„æ›¿ä»£æ–¹æ¡ˆï¼ˆä¿ç•™ç”Ÿè‚²ï¼‰æˆ–è¼”åŠ©æ²»ç™‚

å®‰å…¨æ€§è³‡è¨Šè«‹åƒè€ƒåŸå» ä»¿å–®ã€‚


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Weight Gain** ğŸ”´ Major
- æ³¨æ„äº‹é …ï¼šProgestogens can cause weight gain, which may be significant (as is the case with parenteral medroxyprogesterone) and undesirable in obese patients at...

**Weight Gain** ğŸ”´ Major
- æ³¨æ„äº‹é …ï¼šProgestogens can cause weight gain, which may be significant (as is the case with parenteral medroxyprogesterone) and undesirable in obese patients at...

**Depressive Disorder** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚

**Water-Electrolyte Imbalance** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šEstrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods...

**Glucose Intolerance** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚

**Eye Diseases** ğŸŸ¡ Moderate
- é¢¨éšªåŒ…æ‹¬ï¼šè¡€æ “ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Thyroid Diseases** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šWhen administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect t...

**Hyperlipidemias** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**Depressive Disorder** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚

**Water-Electrolyte Imbalance** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šEstrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods...

**Glucose Intolerance** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚

**Eye Diseases** ğŸŸ¡ Moderate
- é¢¨éšªåŒ…æ‹¬ï¼šè¡€æ “ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Thyroid Diseases** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šWhen administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect t...

**Hyperlipidemias** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**Breast Neoplasms** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Thromboembolism** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚é¢¨éšªåŒ…æ‹¬ï¼šè¡€æ “ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**Breast Neoplasms** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Thromboembolism** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚é¢¨éšªåŒ…æ‹¬ï¼šè¡€æ “ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**è‘¡è„æŸšæ±** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šå½±éŸ¿è—¥ç‰©ä»£è¬ã€‚å¯èƒ½å¢åŠ è—¥ç‰©è¡€ä¸­æ¿ƒåº¦ã€‚
- å»ºè­°ï¼šæ‡‰å®Œå…¨é¿å…ã€‚éœ€ç›£æ¸¬ç™‚æ•ˆæˆ–ä¸è‰¯åæ‡‰ã€‚é¿å…é£Ÿç”¨è‘¡è„æŸšæˆ–è‘¡è„æŸšæ±ã€‚


## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
- è±å¯Œçš„è‡¨åºŠæ–‡ç»æ”¯æŒé»ƒé«”ç´ ç”¨æ–¼å­å®®å…§è†œç™Œæ²»ç™‚
- Cochrane ç³»çµ±å›é¡§å·²è©•ä¼°æ­¤é©æ‡‰ç—‡
- åœ¨å¹´è¼•å¥³æ€§ä¿ç•™ç”Ÿè‚²çš„æƒ…å¢ƒä¸­æœ‰æ˜ç¢ºè§’è‰²
- ä½†å°ç£è—¥è­‰ç›®å‰æœªåŒ…å«æ­¤é©æ‡‰ç—‡

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- è©•ä¼°æ˜¯å¦ç”³è«‹é©æ‡‰ç—‡æ“´å±•
- ç¢ºèªèˆ‡ç¾æœ‰é»ƒé«”ç´ è£½åŠ‘ï¼ˆå¦‚ MPAï¼‰çš„ç™‚æ•ˆæ¯”è¼ƒ
- å»ºç«‹é©ç•¶çš„æ‚£è€…é¸æ“‡æ¨™æº–ï¼ˆè…«ç˜¤åˆ†ç´šã€å—é«”ç‹€æ…‹ï¼‰
- é•·æœŸè¿½è¹¤å¾©ç™¼ç‡å’Œå­˜æ´»ç‡æ•¸æ“š

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Regorafenib]({{ "/drugs/regorafenib/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Hydroxyurea]({{ "/drugs/hydroxyurea/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Vonoprazan]({{ "/drugs/vonoprazan/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Carboplatin]({{ "/drugs/carboplatin/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Prednisone]({{ "/drugs/prednisone/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Hydroxyprogesterone Caproateè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/hydroxyprogesterone_caproate/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_hydroxyprogesterone_caproate,
  title = {Hydroxyprogesterone Caproateè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/hydroxyprogesterone_caproate/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
